Eli Lilly and Co. will expand its Indianapolis manufacturing operations for the first time in more than two decades, the company announced Tuesday.
The Indianapolis-based drugmaker said the "multi-million" expansion will allow the plant to make insulin cartridges to meet what it describes as growing demand in the United States.
Lilly did not offer details about the expansion or say whether it include new jobs.
U.S. sales of Lilly’s insulins, Humalog and Humulin, fell in Lilly’s most recent quarter by 2 percent and 7 percent, respectively. Lilly officials said the products were losing market share in the first half of the year after a large third-party payer removed Lilly’s insulins from its formulary.
Also, a contract Lilly had with Wal-Mart Stores Inc. to supply insulin for its ReliOn brand was terminated.